MedTrace Logo

DAY101 In Gliomas and Other Tumors

NCT03429803 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-02-19

No results posted yet for this study

Summary

This research study is studying a drug Tovorafenib/DAY101 (formerly TAK-580, MLN2480) as a possible treatment a low-grade glioma that has not responded to other treatments.

The name of the study drug involved in this study is:

• Tovorafenib/DAY101 (formerly TAK-580, MLN2480)

Conditions

  • Low-grade Glioma

Interventions

DRUG

DAY101

28 day cycle, oral, once per week

Sponsors & Collaborators

  • PLGA Fund at Pediatric Brain Tumor Foundation

    collaborator UNKNOWN

  • National Cancer Institute (NCI)

    collaborator NIH

  • Pacific Pediatric Neuro-Oncology Consortium

    collaborator OTHER

  • Team Jack Foundation

    collaborator UNKNOWN

  • Day One Biopharmaceuticals, Inc.

    collaborator INDUSTRY

  • Karen D. Wright, MD

    lead OTHER

Principal Investigators

  • Karen D. Wright, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-27
Primary Completion
2025-12-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03429803 on ClinicalTrials.gov